2月3日，德琪医药-B(06996)盘中下跌6.41%，截至11:20，报0.73元/股，成交104.08万元。
德琪医药公司是一家专注于血液和实体肿瘤领域的生物制药企业，主要业务是进行早期研发、临床研究、药物生产及商业化。目前，公司已经建立起一条包括9款肿瘤药物的研发管线，其中6款产品具有全球权益，3款产品拥有亚太权益，其产品希维奥（塞利尼索片）已在多个地区获批上市。
截至2024年中报，德琪医药-B营业总收入6077.9万元、净利润-1.67亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.